2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-091)
PHASE3CompletedINTERVENTIONAL
Enrollment
922
Participants
Timeline
Start Date
May 13, 2004
Primary Completion Date
April 6, 2005
Study Completion Date
April 20, 2005
Conditions
Postoperative Nausea and Vomiting
Interventions
DRUG
MK0869, aprepitant
DRUG
Comparator: ondansetron IV
All Listed Sponsors
lead
Merck Sharp & Dohme LLC
INDUSTRY
NCT00090246 - 2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-091) | Biotech Hunter | Biotech Hunter